These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8693536)

  • 1. Reversal of the OKT3-related shivering and chest tightness by intravenous meperidine.
    Abdallah KA; David-Neto E; Centeno JR; Nahas WC; Arap S
    Transplantation; 1996 Jul; 62(1):145-6. PubMed ID: 8693536
    [No Abstract]   [Full Text] [Related]  

  • 2. [Aseptic meningitis due to OKT3].
    Uribe Roca MC; Zurru MC; Gatto EM; Maggiora EC; Agost Carreño C; Luciano M
    Neurologia; 1998 Feb; 13(2):98-9. PubMed ID: 9578680
    [No Abstract]   [Full Text] [Related]  

  • 3. OKT3 (muromonab-CD3) associated hepatitis in a kidney transplant recipient.
    Go MR; Bumgardner GL
    Transplantation; 2002 Jun; 73(12):1957-9. PubMed ID: 12131696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Very early meningoencephalopathy associated with the intraoperative use of OKT3 in renal retransplant.
    Assmann JB; Fontana V; Pansard HM; Ferreira MB; Bianchin MM
    Arq Neuropsiquiatr; 2008 Sep; 66(3B):747-8. PubMed ID: 18949276
    [No Abstract]   [Full Text] [Related]  

  • 5. Anaphylactoid reaction to muromonab-CD3 in a pediatric renal transplant recipient.
    Berkowitz RJ; Possidente CJ; McPherson BR; Guillot A; Braun SV; Reese JC
    Pharmacotherapy; 2000 Jan; 20(1):100-4. PubMed ID: 10641983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3).
    Hartnick CJ; Cohen AF; Smith RV
    Ann Otol Rhinol Laryngol; 1997 Aug; 106(8):640-2. PubMed ID: 9270425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OKT3 monoclonal antibody therapy and visual loss.
    Horina JH; Horn S; Holzer H; Langmann G
    Nephrol Dial Transplant; 1996 Jul; 11(7):1497-8. PubMed ID: 8815436
    [No Abstract]   [Full Text] [Related]  

  • 8. Uveitis associated with OKT3 therapy for renal transplant rejection.
    Gariano RF; Weitzman ML
    Br J Ophthalmol; 2001 Apr; 85(4):500-1. PubMed ID: 11302132
    [No Abstract]   [Full Text] [Related]  

  • 9. Haemolytic uraemic syndrome associated with OKT3.
    Morris-Stiff G; Evans M; Baboolal K; Balaji V; Moore R; Jurewicz A; Lord R
    Transpl Int; 1996; 9(5):522-3. PubMed ID: 8875800
    [No Abstract]   [Full Text] [Related]  

  • 10. Visual loss complicating OKT3 monoclonal antibody therapy in a renal transplant recipient.
    Jin DC; Kim SY; Lee JM; Koo WS; Choi EJ; Yoon YS; Bang BK
    Nephrol Dial Transplant; 1995 Nov; 10(11):2144-6. PubMed ID: 8643188
    [No Abstract]   [Full Text] [Related]  

  • 11. Muromonab CD3 (Orthoclone OKT3).
    Takahashi K
    J Toxicol Sci; 1995 Sep; 20(4):483-4. PubMed ID: 8531248
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer risk associated with ATG/OKT3 in renal transplantation.
    Hibberd AD; Trevillian PR; Wlodarzcyk JH; Gillies AH; Stein AM; Sheil AG; Disney AP
    Transplant Proc; 1999; 31(1-2):1271-2. PubMed ID: 10083567
    [No Abstract]   [Full Text] [Related]  

  • 13. Generalized seizures associated with the use of muromonab-CD3 in two patients after kidney transplantation.
    Seifeldin RA; Lawrence KR; Rahamtulla AF; Monaco AP
    Ann Pharmacother; 1997 May; 31(5):586-9. PubMed ID: 9161654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute thrombosis of the renal transplant artery after a single dose of OKT3.
    Shankar R; Bastani B; Salinas-Madrigal L; Sudarshan B
    Am J Nephrol; 2001; 21(2):141-4. PubMed ID: 11359022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequences of OKT3 administration via continuous infusion as compared to bolus infusion.
    ten Berge RJ; Buysmann S; van Diepen FN; Surachno S; Hack CE
    Transplant Proc; 1996 Dec; 28(6):3217-20. PubMed ID: 8962246
    [No Abstract]   [Full Text] [Related]  

  • 16. HaNDL syndrome after "benign" OKT3-induced meningitis.
    Thomas MC; Walker R; Wright A
    Transplantation; 1999 May; 67(10):1384-5. PubMed ID: 10360598
    [No Abstract]   [Full Text] [Related]  

  • 17. OKT3 and hepatitis C: defining the risks.
    Rosen HR; Martin P
    Transplantation; 1997 Jan; 63(1):171-2. PubMed ID: 9000685
    [No Abstract]   [Full Text] [Related]  

  • 18. Tramadol versus meperidine in the treatment of shivering during spinal anaesthesia.
    Kaya M; Sariyildiz O; Karakus D; Ozalp G; Kadiogullari DN
    Eur J Anaesthesiol; 2003 Apr; 20(4):332-3. PubMed ID: 12703840
    [No Abstract]   [Full Text] [Related]  

  • 19. [Convulsions induced ty OKT3?].
    Merello M; Nogués M; Leiguarda R; Dávalos M; Jost L
    Medicina (B Aires); 1991; 51(6):581. PubMed ID: 7476118
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of the OKT3 first-dose syndrome by reduced initial dose followed by adjusted doses based on CD3 T-lymphocyte counts in pediatric renal graft recipients.
    Piatosa B; Grenda R; Prokurat S
    Transplant Proc; 1996 Dec; 28(6):3466-7. PubMed ID: 8962349
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.